[Therapeutic drug monitoring of three antiepileptic drugs - Back on twenty years of experience].
BACKGROUND
The therapeutic drug monitoring (TDM) of antiepileptic drugs is a tool widely used in the management of epilepsy. In Morocco, this monitoring is carried out by the Centre Anti Poison et Pharmacovigilance (CAPM) since April 1995.


METHODS
This is a retrospective study spanning 20 years. It concerns the therapeutic drug monitoring of Phenobarbital (PB) of carbamazepine (CBZ) and valproic acid (VPA).


RESULTS
Therapeutic drug monitoring of the 3 antiepileptic drugs represent 58.85% of all applications received by the CAPM. The dosage of PB was ranked first followed by that of CBZ and finally by the VPA. Weak demand for therapeutic drug monitoring in Morocco could be explained by the low number of neurologists in addition to social factors. With its affordable price by patients, PB is the most prescribed antiepileptic drug in our country, which explains the high demand for its dosage. As for the therapeutic drug monitoring of the antiepileptic drug, they were mainly related to age, the occurrence of adverse effects, the association antiepileptic drugs or in the case of verification of patient compliance.


CONCLUSIONS
Efforts are required for promoting the interests of therapeutic drug monitoring of antiepileptic drug in the management of epilepsy in Morocco.
Laboratoire de Pharmacologie et de Toxicologie, Faculté de Médecine et de Pharmacie, Université Mohammed V, Rabat, Maroc.
Samira
S
Serragui
Centre Anti Poison et de Pharmacovigilance du Maroc.
Fatima
F
Zalagh
Laboratoire de Pharmacologie Faculté de Médecine et de Pharmacie, Université Abdelmalek Essaadi, Tanger, Maroc.
Driss Soussi
DS
Tanani
Centre Anti Poison et de Pharmacovigilance du Maroc.
Lahcen
L
Ouammi
Centre Anti Poison et de Pharmacovigilance du Maroc.
Latifa Ait
LA
Moussa
Centre Anti Poison et de Pharmacovigilance du Maroc.
Narjis
N
Badrane
Laboratoire de Pharmacologie et de Toxicologie, Faculté de Médecine et de Pharmacie, Université Mohammed V, Rabat, Maroc; Centre Anti Poison et de Pharmacovigilance du Maroc.
Rachida Soulaymani
RS
Bencheikh
D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002220:Carbamazepine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring / Q000379:methods*; D004827:Epilepsy / Q000188:drug therapy; D006801:Humans; D055118:Medication Adherence; D009018:Morocco; D010634:Phenobarbital / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D012189:Retrospective Studies; D014635:Valproic Acid / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
D000927:Anticonvulsants; D002220:Carbamazepine; D014635:Valproic Acid; D010634:Phenobarbital
Antiepileptics; Therapeutic drug monitoring